Bruker Announces Collaborative Advances in CCS-Enabled 4D Proteomics Workflows at HUPO
16 November 2021 - 11:00PM
Business Wire
- Co-marketing agreement with Cellenion on cellenONE® sample
preparation system for automated label-free workflows for
single-cell 4D proteomics on timsTOF SCP
- Seer Proteograph™ Product Suite combined with timsTOF Pro 2
and timsTOF SCP enables, deep, unbiased, rapid detection of
>3000 protein groups from human plasma
- Co-marketing new PreOmics BeatBox for high-throughput,
high-performance tissue, biopsy and cell culture homogenization
prior to enzymatic digestion and timsTOF 4D proteomics
At the virtual 20th Human Proteome Organization World Congress,
HUPO Reconnect 2021 (hupo2021.org) Bruker Corporation (Nasdaq:
BRKR) announced major advances in collision cross section (CCS)
enabled 4D proteomics workflows on the unique timsTOF multiomics
platform.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211116005569/en/
cellenONE - Isolate 96 single cells in a
few minutes. (Photo: Business Wire)
Dr. Gary Kruppa, Bruker’s Vice President for Proteomics, stated:
“Widespread adoption of proteomics has been limited by complex
sample preparation protocols that were not easily automated. We are
excited to announce that Bruker is collaborating with
industry-leading partners on higher performance, automated
workflows in three key areas: single-cell proteomics, plasma
proteomics and tissue proteomics.”
A. New Collaboration with Cellenion for 4D Single-Cell
Proteomics (SCP)
Bruker announces a co-marketing agreement with Cellenion on the
cellenONE single-cell isolation and nanoliter dispensing robotic
platform. The partnership with Cellenion on label-free 4D
single-cell proteomics (SCP) provides timsTOF SCP users with an
end-to-end solution. The cellenONE is a unique single-cell
isolation and nanoliter dispensing technology. It enables
high-throughput, automated dispensing of individual cells from cell
suspensions with its unique advantage of minimal perturbation to
the integrity of the live cell. It is also perfectly suited for
reagent dispensing, enabling miniaturized sample preparation
protocols on those isolated cells.
Dr. Holger Eickhoff, CEO of Cellenion and Scienion, said: “We
believe our expertise in precision dispensing and platform
technology for up to 100% single-cell isolation accuracy and
Bruker’s expertise in developing mass spectrometers such as the
timsTOF SCP for single-cell proteomics are a perfect match. This
partnership will benefit our mutual users as the cellenONE provides
automated single-cell isolation and miniaturized sample preparation
using our patented nanoliter dispensing technology.”
B. Collaboration Progress with Seer on Unbiased, Deep Plasma
Proteomics
Deep interrogation of the plasma proteome is challenging,
because of the wide dynamic range of proteins, making it difficult
to detect low-abundance proteins that may serve as biomarkers for
disease. Fast plasma proteomics workflows typically detect only
hundreds of protein groups, whereas workflows that deplete
high-abundance proteins or fractionate the plasma proteins before
analysis are costly, time-consuming and do not scale well. The
combination of Seer’s Proteograph™ Product Suite and timsTOF
platforms allow researchers to dig deeper into the plasma proteome,
detecting protein variation at the amino acid level, with an
unprecedented combination of depth, scale, and speed to power
discovery. “The Proteograph is providing access to the plasma
proteome in a way that has just not been possible before,” said
Gary Kruppa, Vice President for Proteomics at Bruker. “We are
excited about the opportunities that the combination of timsTOF and
Proteograph enables.”
"In a recently presented joint study, we demonstrated that the
Proteograph™ Product Suite enables quantification of more than
3,000 proteins from a single pooled human plasma sample within only
60 minutes of acquisition time on the timsTOF SCP,” said Dr. Daniel
Hornburg, Sr. Director, Discovery Research and Tech Development at
Seer. “We’ve seen excellent performance of the timsTOF Pro in our
labs and the timsTOF SCP as part of the collaborative work with
Bruker. The timsTOF Pro and SCP coupled with our Proteograph
provide sensitivity that takes plasma proteomics to the next
level.”
C. Expanded Partnership with PreOmics on Novel BeatBox™
Technology for Tissue Proteomics
To demonstrate the performance of the innovative BeatBox system
for high-throughput tissue homogenization, PreOmics processed a
variety of tissue samples on the BeatBox and compared results to
those obtained with other commercial homogenization solutions. The
protein extracts from the tissue samples were processed using iST
proteomic sample preparation and the data was acquired on a timsTOF
Pro with 45 minutes total acquisition time using DDA-PASEF. The
complete BeatBox-timsTOF workflow from tissue sample to
high-quality proteomic data is below 4 hours and can homogenize 96
tissue samples in parallel in 10 minutes. The new BeatBox
technology provided the highest protein yields with up to 3x
increases and showed very good reproducibility across different
tissues in comparison to other homogenization solutions.
The BeatBox-timsTOF Pro workflow resulted in excellent proteomic
coverage, e.g., more than 4000 protein IDs for mouse lung and 2300
protein IDs for mouse heart muscle. Drs. Nils A Kulak and Garwin
Pichler, Founders and Managing Directors of PreOmics, commented:
“We are very excited about our innovative BeatBox technology for
highly efficient and reproducible proteomics tissue homogenization.
The BeatBox is seamlessly compatible with PreOmics’ proteomic
sample preparation technologies and in combination with the timsTOF
Pro provides end-to-end workflows for processing of large tissue
biobanks.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. Please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211116005569/en/
Media Contact Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investor Relations Contact Bruker Corporation T: +1 (978)
663–3660, ext. 1479 E: Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024